Fibrinogen and cardiovascular risk

Vascular Medicine

Volumn 2, Issue 2, 1997, Pages 115-125

  Ernst, E ^a   Koenig, W ^b  

^a UNIVERSITY OF EXETER   (United Kingdom)

^b UNIVERSITY HOSPITAL ULM   (Germany)

Author keywords

Atherosclerosis; Coagulation; Fibrinogen; Hemorheology; Thrombogenesis risk factors

Indexed keywords

FIBRINOGEN;

ATHEROSCLEROSIS; BLOOD CLOTTING; BLOOD RHEOLOGY; CARDIOVASCULAR DISEASE; DISEASE ASSOCIATION; FIBRINOGEN BLOOD LEVEL; HUMAN; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; THROMBOCYTE AGGREGATION; THROMBOSIS;

EID: 0030827083     PISSN: 1358863X     EISSN: None     Source Type: Journal    
DOI: 10.1177/1358863X9700200207     Document Type: Review

References (165)

1. Heller RF, Chinn S, Tunstall-Pedoe HD, Rose G. How well can we predict coronary heart disease? BMJ 1984; 288: 410-11
2. Ernst E. Plasma fibrinogen - an independent cardiovascular risk factor. J Int Med 1990; 227: 365-72.
3. Dang CV, Bell WR. The normal and morbid biology of fibrinogen. Am J Med 1989; 87: 567-76.
4. Rabbani LE, Loscalzo J. Recent observations on the role of hemostatic determinants in the development of atherothrombotic plaque. Atherocslerosis 1994; 105: 1-7.
5. Meade TW, North WRS, Chakrabarti R et al. Haemostatic function and cardiovascular death: early results of a prospective study. Lancet 1980; 1: 1050-53
6. Meade TW, Mellows W, Brozovic M et al. Haemostatic function and ischaemic heart disease: principal results of the Northwick Park Heart Study. Lancet 1986; ii: 533-37.
7. Meade TW, Cooper JA, Chakrabari R, Miller GJ, Stirling Y, Howarth DJ Fibrinolytic activity and clotting factors in ischaemic heart disease in women. BMJ 1996; 312: 1581.
8. Baker LA, Eastham R, Elwood PC et al. Haemostatic factors associated with ischemic heart disease in men aged 45 to 64 years. The Speedwell collaborative surveys. Br Heart J 1982; 47: 490-94.
9. Yarnell JWG, Sweetnam PM, Rogers S et al Some long-term effects of smoking on the haemostatic system: a report from the Caerphilly and Speedwell collaborative surveys. J Clin Pathol 1987; 40: 909-13.
10. Yarnell JWG, Baker JA, Sweetnam PM et al. Fibrinogen, viscosity, and white blood cell count are major risk factors for ischemic heart disease. Circulation 1991; 83 836-44.
11. Sweetnam RM, Thomas HF, Yarnell JWG, Beswick AD, Baker IA, Elwood PC. Fibrinogen, viscosity and the 10-year incidence of ischaemic heart disease. The Caerphilly and Speedwell Studies. Eur Heart J 1996; 17. 1814-20.
12. Heinrich J, Balleisen L, Schulte H, Assmann G, Van De Loo J. Fibrinogen and factor VII in the predicition of coronary risk. Arterioscler Thromb 1994; 14: 54-59.
13. Thompson SG, Kienast J, Pyke SDM, Haverkate T, Van De Loo JCW. Hemostatic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris. N Engl J Med 1995; 332: 635-41.
14. Heinrich J, Balleisen L, Schulte H, Assmann G, Van de Loo JCW. Fibrinogen and factor VII in the prediction of coronary risk. Results from the PROCAM Study in healthy men (Correction). Arterioscler Thromb 1994; 14: 1392.
15. Wilhelmsen L, Svardsudd K, Korsan-Bengtsen K et al. Fibrinogen as a risk factor for stroke and myocardial infarction. N Engl J Med 1984; 311. 501-505
16. Eriksson H, Korsan-Bengtsen E, Welin L et al 21-year follow-up of CVD and total mortality among men bom in 1913. In: Ernst E, Keonig W, Lowe GDO, Meade TW eds. Fibrinogen, a 'new' cardiovascular risk factor. Oxford: Blackwell, 1992: 115-19.
17. Rosengren A, Wilhelmsen L. Fibrinogen, coronary heart disease and mortality from all causes in smokers and nonsmokers. The Study of Men Born in 1933. J Intern Med 1996; 239: 499-507.
18. Stone MC, Thorp JM. Plasma fibrinogen - a major coronary risk factor. J R Coll Gen Prac 1985; 35: 565-69.
19. Kannel WB, D'Agnostino RB, Belanger AJ. Fibrinogen, cigarette smoking, and risk of cardiovascular disease: insights from the Framingham Study. Am Heart J 1987; 113: 1006-10.
20. Kannel WB, Wolf PA, Castelli WP, D'Agostino RB. Fibrinogen and risk of cardiovascular disease. J Am Med Assoc 1987; 258 1183-86.
21. Kannel WB. Fibrinogen - a major cardiovascular risk factor. In: Ernst E, Koenig W, Lowe GDO, Meade TW eds. Fibrinogen, a 'new' cardiovascular risk factor. Oxford: Blackwell, 1992: 101-109.
22. Balleisen L, Schulte H, Balleisen L, Assmann G, Van De Loo J Coagulation factors and the progress of coronary heart disease Lancet, 1987; i: 461.
23. Cremer P, Nagel D, Labrot B et al. Lipoprtoein Lp(a) as a predictor of myocardial infarction in comparison to fibrinogen, LDL cholesterol and other risk factors. Eur J Clin Invest 1994; 24: 444-53.
24. Ernst E, Resch KL. Fibrinogen as a cardiovascular risk factor: a metaanalysis and review of the literature. Ann Intern Med 1993; 118: 956-63.
25. Lee AJ, Lowe GDO, Woodward M, Tunstall-Pedoe H. Fibrinogen in relation to personal history of prevalent hypertension, diabetes, stroke, intermittent claudication, coronary heart disease, and family history: the Scottish Heart Study Br Heart J 1993; 69: 338-42.
26. Salomaa V, Rasi V, Pekkanen J et al. Haemostatic factors and prevalent coronary heart disease; the FINRISK haemostatic study. Eur Heart J 1994; 15. 1293-99.
27. Folsom AR, Wu KK, Shahar E, Davis CE. Association of hemostatic variables with prevalent cardiovascular disease and asymptomatic carotid artery atherosclerosis. Arterioscler Thromb 1993; 13. 1829-36.
28. Sharp DS, Abbott RD, Burchfield CM et al. Plasma fibrinogen and coronary heart disease in elderly Japanese-American men. Arterioscler Thromb Vasc Biol 1996; 16: 262-68.
29. Wu KK, Folsom AR, Heiss G, Davis CE, Conlan MG, Barnes R. Association of coagulation factors and inhibitors with carotid artery atherosclerosis. Early results of the ARIC study. Ann Epidemiol 1992; 2: 471-80.
30. Bots ML, Breslau PJ, Briet E et al. Cardiovascular determinants of carotid artery disease: The Rotterdam Elderly Study. Hypertension 1992, 19. 717-20.
31. Levenson J, Giral P, Razavian M, Gariepy J, Simon A. Fibrinogen and silent atherosclerosis in subjects with cardiovascular risk factors. Arterioscler Thromb Vasc Biol 1995; 15. 1263-68.
32. Tracy RP, Bovill EG, Yanez D et al. Fibrinogen and Factor VIII, but not factor VII, are associated with measures of subclinical cardiovascular disease in the elderly. Results from the Cardiovascular Health Study Arterioscler Thromb Vasc Biol 1995; 15: 1269-79.
33. Lowe GDO, Smith WCS, Tunstall-Pedoe HD et al. Cardiovascular risk and haemorheology - results from the Scottish Heart Health Study and the MONICA-Project, Glasgow. Clin Hemorheol 1988; 8: 507-15.
34. Ernst E, Koenig W, Matrai A, Keil U. Plasma viscosity and hemoglobin in the presence of cardiovascular risk factors. Clin Hemorheol 1988; 8: 507-15.
35. Krobot K, Hense HW, Cremer P, Eberle E, Keil U. Determinants of plasma fibrinogen: relation to body weight, waist-to-hip ratio, smoking, alcohol, age, and sex: Results from the Second MONICA Augsburg Survey 1989-1990 Arterioscler Thromb 1992; 12: 780-87.
36. Lee AJ, Smith WCS, Lowe GDO, Turnstall-Pedow H. Plasma fibrinogen and coronary risk factors: The Scottish Health Study. J Clin Epidem 1990; 43: 913-19
37. Möller L, Kristensen TS. Plasma fibrinogen and ischemic heart disease risk factors. Arterioscler Thromb 1991; 11: 344-50.
38. Folsom A, Wu KK, Davis CE, Conlan MG, Sorlie PD, Szklo M. Population correlates of plasma fibrinogen and factor VII, putative cardiovascular risk factors. Atherosclerosis 1991; 91: 199-205
39. Dormandy J, Ernst E, Matrai A, Flute P. Hemorheological changes following acute myocardial infarction. Am Heart J 1982; 104: 1364-67.
40. Kruskal JB, Patrick CB, Commerford J, Franks JJ, Kirsch RE. Fibrin and fibrinogen-related antigens in patients with stable and unstable coronary artery disease. N Engl J Med 1987; 317: 1361-65.
41. Lowe GDO, Drummond MM, Lorimer AR et al. Relation between extent of coronary artery disease and blood viscosity. Br Med J 1980; 280: 673-74.
42. Handa K, Kiono S, Saku K. Plasma fibrinogen levels as an independent indicator of severity of coronary atherosclerosis. Atherosclerosis 1989; 77: 209-13
43. Broadhurst P, Kelleher C, Hughes L, Imeson JD, Raftery EB. Fibrinogen, factor VII clotting activity and coronary artery disease severity. Atherosclerosis 1990, 85: 169-73.
44. Ernst E, Resch KL, Krauth U, Paulsen HF. Does blood rheology revert to normal after myocardial infarction? Br Heart J 1990, 64: 248-50.
45. Martin JF, Bath PMW, Burr ML. Influence of platelet size on outcome after myocardial infarction. Lancet 1992; 338: 1409-11
46. Burr ML, Holliday RM, Fehily AM, Whitehead PJ. Haematological prognostic indices after myocardial infarction: evidence from the diet and reinfarction trial (DART). Eur Heart J 1992; 13: 166-70.
47. Benchimol D, Dartigues JF, Benchimol H. Predictive value of hemostatic factors for sudden death in patients with stable angina pectoris. Am J Cardiol 1995; 76: 241-44.
48. Benderly M, Graff E, Reicher-Reiss H, Behar S, Brunner D, Goldbourt U. Fibrinogen is a predictor of mortality in coronary heart disease patients. Arterioscler Thromb Vasc Biol 1996; 16: 351-56.
49. Thompson SG, Fechtrup C, Squire E et al. Antithrombin III and fibrinogen as predictors of cardiac events in patients with angina pectoris. Arterioscler Thromb Vasc Biol 1996; 16: 357-62.
50. Montalescot G, Ankri A, Vicaut E, Drobinski G, Grosgogeat Y, Thomas D. Fibrinogen after coronary angioplasty as a risk factor for restenosis. Circulation 1995; 92: 31-38.
51. Liuzzo G, Buffon A, Vitelli A et al. Plasma levels of interleukin-6 predict restenosis following coronary angioplasty in patients with unstable angina. Circulation 1996, 94: I-330.
52. Eisenbert S. Blood viscosity and fibrinogen concentration following cerebral infarction. Circulation 1966; 33/34 (suppl 2): 10-14.
53. Ernst E, Matrai A, Marshall M. Blood rheology in patients with transient ischemic attacks. Stroke 1988; 19. 634-36.
54. Coull BM, Beamer N, de Garmo P et al. Chronic hyperviscosity in subjects with acute stroke, transient ischemic attack, and risk factors for stroke. Stroke 1991; 22: 162-68.
55. Qizilbash N, Jones L, Warlow C, Mann J. Fibrinogen and lipid concentrations as risk factors for transient ischaemic attacks and minor ischaemic strokes. Br Med J 1991; 303. 605-609.
56. Resch KL, Ernst E, Matrai A, Paulsen HF. Fibrinogen and viscosity, risk factors for stroke survivors. Ann Intern Med 1992; 177: 371-75.
57. Grotta JC. Prediction of carotid stenosis progression by lipid and hematologic measurements. Neurology 1989; 39: 1325-31.
58. Stuart J, George AJ, Davies AJ, Aukland A, Hurlow RA. Haematological stress syndrome in atherosclerosis. J Clin Pathol 1981; 34: 464-67.
59. Dormandy JA, Hoare E, Colley J, Arrowsmith DE, Dormandy TL. Clinical haemodynamic, rheological and biochemal findings in 126 patients with intermittent claudication. BMJ 1973, 4: 576-81.
60. Leng GC, Lee AJ, Fowkes FGR, Lowe GDO, Housley E. The relationship between cigarette smoking and cardiovascular risk factors in peripheral arterial disease compared with ischaermc heart disease. Eur Heart J 1995; 16: 1542-48.
61. Lowe GDO, Fowkes FGR, Dawes J, Donnan PT, Lennie SE, Housley E. Blood viscosity, fibrinogen, and activation of coagulation and leukecytes in peripheral arterial disease and the normal population in the Edinburgh Artery Study. Circulation 1993; 87: 1915-20.
62. Lassila R, Peltonen S, Lepäntalo M, Saarinen O, Kauhanen P, Manninen V. Severity of peripheral atherosclerosis is associated with fibrinogen and degradation of cross-linked fibrin. Arterioscler Thromb 1993; 13: 1738-42.
63. Bainton D, Sweetnam P, Baker I, Elwood P. Peripheral vascular disease, consequence for survival and association with risk factors in the Speedwell prospective heart disease study. Br Heart J 1994; 72: 128-32.
64. Lowe GDO, Lee AJ, Rumley A, Price JF, Fowkes GR. Blood viscosity and risk of cardiovascular events: the Edinburgh Artery Study. Br J Haematol 1997; 96: 168-73.
65. Wiseman S, Kenehington G, Dain R. Influence of smoking and plasma factors on patency of femoro-poplitean vein grafts. BMJ 1989; 299: 643-46.
66. Violi F, Criqui M, Longoni A, Castiglioni C. Relation between risk factors and cardiovascular complications in patients with peripheral vascular disease. Results from the ADEP study. Atherosclerosis 1996; 120: 25-35.
67. Hamsten A, Iseluis L, de Faire U, Blomback M. Genetic and cultural inheritance of plasma fibrinogen concentration. Lancet 1987; ii: 988-90.
68. Berg K, Kierulf P. DNA polymorphisms at fibrinogen loci and plasma fibrinogen concentration. Clin Genet 1992; 36: 229-35.
69. Reed T, Tracy RP, Fabsitz RR. Minimal genetic influences on plasma fibrinogen level in adult males in the NHLBI twin study. Clin Genet 1994; 45: 71-77.
70. Hoffman CJ, Burns P, Lawson WE, Katz JP, Miller RH, Hultin MB. Plasma fibrinogen level is not elevated in young adults from families with premature ischaemic heart disease. Arterioscler Thromb 1993; 13: 800-803.
71. Humphries SE. Genetic regulation of fibrinogen. Eur Heart J 1995; 16 (suppl A): 16-20.
72. Green F, Hamsten A, Blombäck M, Humphries S. The role of beta-fibrinogen genotype in determining plasma fibrinogen levels in young survivors of myocardial infarction and healthy controls from Sweden. Thromb Haemost 1993; 90: 915-20.
73. Scarabin PY, Bara L, Ricard S et al. Genetic variation at the beta-fibrinogen locus in relation to plasma fibrinogen concentrations and risk of myocardial infarction. The ECTIM study. Arterioscler Thromb 1993; 13: 886-91.
74. Fowkes FGR, Connar JM, Smith FB, Wood J, Donnan PT, Lowe GDO. Fibrinogen genotype and risk of peripheral atherosclerisis. Lancer 1992; 339: 639-46.
75. Behague I, Poirier O, Nicaud V et al. Beta-fibrinogen gene polymorphisms are associated with plasma fibrinogen and coronary artery disease in patients with myocardial infarction. The ECTIM Study. Circulation 1996; 93: 440-49.
76. Humphries SE, Cook M, Dubowitz M, Stirling Y, Meade TW. Role of genetic variation at the fibrinogen locus in determination of plasma fibrinogen concentrations. Lancet 1987; 1: 1452-55.
77. Thomas A, Kelleher C, Green F, Meade TW, Humphries SE. Variation in the promoter region of the beta-fibrinogen gene is associated with plasma fibrinogen levels in smokers and non-smokers. Thromb Haemost 1991; 65: 487-90.
78. Montgomery HE, Clarkson P, Nwose OM et al The acute rise in plasma fibrinogen concentration with exercise is influenced by the G-453-A polymorphisms of the beta-fibrinogen gene Arterioscler Thromb Vasc Biol 1996; 16. 386-91.
79. Hamilton PJ, Dawson AA, Ogston D, Douglas AS. The effect of age on the fibrinolytic enzyme system. J Clin Pathol 1974; 27: 326-29.
80. Meade TW, Chakrabarti R, Haines AP, North WRS, Stirling Y Characteristics affecting fibrinolytic activity and plasma fibrinogen concentrations. Br Med J 1979; 1: 153-56.
81. Bongrand P, Barolin R, Bouvenot G et al. Effect of age on different receptors and functions of phagocytic cells. J Clin Lab Immunol 1984; 15: 45-50.
82. De Boever E, Bacquer D, Braeckman L, Baele G, Rosseneu M, De Backer G Relation of fibrinogen to lifestyles and to cardiovascular risk factors in a working population. Int J Epidemiol, 1995; 24: 915-21.
83. Ernst E, Koenig W, Matrai A, Keil U. Hämorheologische Variablen bei manifesten arteriellen Gefasserkrankungen. Vasa 1986; 15: 365-72.
84. Lowe GDO, Drummond MN, Third JLH et al. Increased plasma fibrinogen, and platelet aggregates in type II hyperlipoproteinaemia. Thromb Haemost 1979; 42: 1503-507.
85. Di Minno G, Silver MJ, Cerbone AM, Ramone A, Postliglione A, Mancini M. Increased fibrinogen binding to platelets from patients with familial hyoercholesterolemia. Arteriosclerosis 1986; 6. 203-11.
86. Eikeles RS, Chakrabarti R, Vickers M, Stirling Y, Meade TW. Effect of treatment of hyperlipidaemia in haemostatic variables. Br Med J 1980; 281: 973-74.
87. Koenig W, Sund M, Ernst E, Mraz W, Hombach V, Keil U Association between rheology and components of lipoproteins in human blood. Results from the MONICA project Augsburg. Circulation 1992; 85: 2197-204.
88. Halle M, Berg A, Keul J, Baumstark MW. Association between serum fibrinogen concentrations and HDL and LDL subfraction phenotypes in healthy men. Arterioscler Thromb Vasc Biol 1996; 16: 144-48.
89. Ernst E, Matrai A, Schmölzl C, Magyarosy I. Dose-effect relationship between smoking and blood rheology. Br J Haematol 1987; 65: 485-87.
90. Ernst E, Matrai A. Abstention from chronic cigarette smoking normalizes blood rheology. Atherosclerosis 1987; 64: 75-77.
91. Powell JT, Sian M, Wiseman S, Grennhalgh RM. Fibrinogen and carboxyhaemoglobin in peripheral arterial disease. Lancet 1988; i: 121.
92. Ernst E, Koenig W, Matrai A, Filipiak B, Stieber J. Plasma viscosity and related variables in healthy cigarette smokers - results from the MONICA-project Augsburg. Arteriosclerosis 1988; 8: 385-88.
93. Letcher RL, Chien S, Pickering TG, Sealey JE, Laragh JH. Direct relationship between blood pressure and blood viscosity in normal and hypertensive subjects: role of fibrinogen concentration. Am J Med 1981; 70: 1195-202.
94. Koenig W, Sund M, Ernst E, Keil U, Rosenthal J, Hombach V. Association between plasma viscosity and increased plasma viscosity and blood pressure. Results from the MONICA project Augsburg. Am J Hypertens 1991; 4: 529-36.
95. Landin K, Tengborn L, Smith U. Elevated fibrinogen and plasminogen activator inhibitor in hyertension are related to metabolic risk factors for cardiovscular disease. J Int Med 1990; 227: 273-78.
96. Barnes A, Willars E. Diabetes. In: Chien S, Dormandy J, Ernst E, Matrai A, eds. Clinical hemorheology. Dordrecht: M Nijhoff, 1987, 275-309.
97. Morishita E, Asakura H et al Hypercoagulability and high lipoprotein (a) levels in patients with type II diabetes mellitus. Atheroscler Thromb Vasc Biol 1996; 120: 7-14
98. Missov RM, Stolk RP, van der Bom JA et al. Plasma fibrinogen in NIDDM. Diabetes Care 1996; 19: 157-59.
99. Kannel WB, D'Agostino RB, Wilson PW, Belanger AJ, Gagnon DR. Diabetes, fibrinogen, and risk of cardiovascular disease: the Framinghain experience. Am Heart J 1990; 120: 672-76.
100. Schmitz A, Ingerslev J. Hemostatic measurements in type II diabetic patients with albuminura. Diabet Med 1990; 7: 521-25.
101. Young MJ, Bennett JL, Liderth SA, Veves A, Boulton AJM, Douglas JT. Rheological and microvascular parameters in diabetic peripheral neuropathy. Clin Science 1996; 90: 183-87.
102. Ganda OP, Arkin CF. Hyperfibrinogenemia a major determinant of vascular complications in diabetes. In: Ernst E Koenig W, Lowe GDO, Meade TW (eds). Fibrinogen, a 'new' cardiovascular risk factor. Oxford: Blackwell, 1992: 254-58
103. Valek J, Valkova L, Valaskova Z, Topinka V. Increased fibrinogen levels in the offspring of hypertensive men. Arterioscler Thromb Vasc Biol 1995, 15: 2229-33.
104. Elwood PC, Yarnell JWG, Pickering J, Fehily AM, O'Brien JR. Exercise, fibrinogen, and other risk factors for ischaemic heart disease. Caerphilly Prospective Heart Disease Study. Br Heart J 1993; 69: 183-87.
105. Connelly JB, Cooper JA, Meade TW. Strenuous exercise, plasma fibrinogen, and factor VII activity. Br Heart J 1992; 67: 351-54.
106. Koenig W, Sund M, Doring A, Ernst E, Leisure-time physical activity but not work-related physical activity is associated with decreased plasma viscosity Results from a large population sample. Circulation 1997; 95: 335-41.
107. Lakka TA, Salonen JT. Moderate to high intensity conditioning leisure time physical activity and high cardiorespiratory fitness are associated with reduced plasma fibrinogen in eastern Finnish men J Clin Epidemiol 1993; 46: 1119-27.
108. Rankinen T, Rauramaa R, Väisänen S et al. Inverse relationship between physical activity and plasma fibrinogen in post-menopausal women. Atherosclerosis 1993; 102: 181-86.
109. Vanninen E, Laitinen J, Uusitupa M. Physical activity and fibrinogen concentration in newly diagnosed NIDDM. Diabetes Care 1994; 17: 1031-38.
110. Dudaev VA, Dyukov IV, Borodkin VV et al. Change of the level of fibrinogen and its high molecular derivatives as a result of physical training in CHD patients. Ter Arkh 1986; 58: 62-66.
111. Stratton JR, Chandler WL, Schwartz RD. Effects of physical conditioning on fibrinolytic variables and fibrinogen in young and old healthy adults. Circulation 1991; 83: 1692-97.
112. Wosornu D, Allardyce W, Ballantyne D, Tansey P. Influence of power and aerobic exercise training on haemostatic factors after coronary artery surgery. Br Heart J 1992; 68: 181-86.
113. Ernst E, Schmid M. Regular aerobic exercise lowers fibrinogen levels Eur J Phys Med Rehab 1993; 3: 196-98.
114. Ernst E, Matrai A Intermittent claudication, exercise and blood rheology Circulation 1987; 76: 1110-14.
115. Meade TW Epidemiology of atheroma and thrombosis. In: Bloom AL, Thomas DP eds. Haemostasis and thrombosis. Edinburgh: Churchill Livingstone, 1984: 575-92.
116. Ernst E. Does weight loss reduce plasma fibrinogen? Br Heart J 1993; 70: 116-18
117. Cigolini M, Targher G, Bergamo Andreis LA, Tonoli M, Agostino G, DeSandre G. Visceral fat accumulation and its relation to plasma hemostatic factors in healthy men. Arterioscl Thromb Vasc Biol 1996; 16: 368-74.
118. Mehrabian M, Peter JB, Barnard RJ, Lusis A. Dietary regulation of fibrinolytic factors. Atherosclerosis 1990, 84: 25-32.
119. Almendingen K, Seljeflot I, Sandstad B, Pedersen JI. Effects of partially hydrogenated fish oil, partially hydrogenated soybean oil, and butter on hemostatic variables in men. Arterioscler Thromb Vasc Biol 1996; 16: 375-80.
120. Wojenski CM, Silver MJ, Walker J. Eicosapentaenoic acid ethylester as an antithrombotic agent, comparison to an extract of fish oil. Biochem Biophys Acta 1991, 1081: 33-38.
121. Racack K, Deck C, Huster G. The comparative effects of n-3 and n-6 polyunsaturated fatty acids on plasma fibrinogen levels, a controlled clinical trial in hypertriglyceridemic subjects. J Am Coll Nutr 1990; 9. 352-57.
122. Markowe HLJ, Marmot MG, Shipley MJ et al. Fibrinogen: a possible link between social class and coronary heart disease. BMJ 1985; 291. 1312-14
123. Wilson TW, Kaplan G, Kauhanen J et al. Association between plasma fibrinogen concentration and five socioeconomic indices in the Kuopio Ischemic Heart Disease Risk Factor Study Am J Epidemiol 1993; 137: 292-300.
124. Ernst E, Weihmayr T, Schmid M, Baumann M, Matrai A. Cardiovascular risk factors and hemorheology. Physical fitness, stress and obesity Atherosclerosis 1986; 59: 263-69.
125. Rosengren A, Wilhelmsen L, Welm L, Tsipogianni A, Teger-Nilsson AC, Wedel H. Social influences on cardiovascular risk factors as determinants of plasma fibrinogen concentration in a general population sample of middle-aged men. BMJ 1990; 300: 634-38.
126. Ernst E. The effects of oral contraceptives on fibrinogen. Atherosclerosis 1992, 93: 1-5.
127. Barker DJP, Mead TW, Fall HD et al. Relation of fetal and infant growth to plasma fibrinogen and factor VII concentration in adult life. BMJ 1992; 304: 148-52.
128. Jousilahti P, Vartiainen E, Tuomilehto J, Puska PL Symptoms of chronic bronchitis and the risk of coronary disease. Lancet 1996; 348: 567-72.
129. Patel P, Mendall MA, Carrington D et al. Association of Helicobacter pylori and Chlamydia pneumoniae infections with coronary heart disease and cardiovascular risk factors. BMJ 1995; 311: 711-14.
130. Murray LJ, Bamford KB, O'Reilly DPF, McCrum EE, Evans AE. Helicobacter pylori infection: relation with cardiovascular risk factors, ischaemic heart disease, and social class. Br Heart J 1995; 74: 497-501.
131. Mendall MA, Goggin PM, Molineaux N et al. Relation of Helicobacter pylori infection and coronary heart disease. Br Heart J 1994; 71: 437-39.
132. Saikku P, Leinonen M, Tenkanen L et al. Chronic Chlamydia pneumoniae infection as risk factor for coronary heart disease in the Helsinki Heart Study. Ann Intern Med 1992; 116: 273-78.
133. Patel P, Carrington D, Strachan DP et al. Fibrinogen, a link between chronic infection and coronary heart disease. Lancet 1994; 343: 1634-5
134. Mattila KJ Dental infections as a risk factor for acute myocardial infarction. Eur Heart J 1993, 14 (suppl K): 51-53.
135. DeStefano F, Anda RF, Kahn HS, Williamson DF, Russell CM. Dental disease and risk of coronary heart disease and mortality. Br Med J 1993; 306: 688-91.
136. Kweider M, Lowe GDO, Murray GD et al. Dental disease, fibrinogen and white cell count: links with myocardial infarction? Scott Med J 1993; 38: 73-74.
137. Stout RW, Crawford V. Seasonal variations in fibrinogen concentrations among elderly people. Lancet 1991; 338: 9-13.
138. Woodhouse PR, Khaw KT Plummer M, Foley A, Meade TW. Seasonal variations of plasma fibrinogen and factor VII activity in the elderly: winter infections and death from cardiovascular disease. Lancet 1994; 343: 435-39.
139. Khaw KT, Woodhouse P. Interrelation of vitamin C, infection, haemostatic factors and cardiovascular disease. BMJ 1995; 310: 1559-63.
140. Koenig W, Ruess S, Sund M, Hoffmeister A, Ernst E, Hombach V. Seasonal variations of hematological, inflammatory and lipid parameters in healthy subjects. Fibrinolysis 1996; 10 (suppl I): 49.
141. Cook NS, Ubben D. Fibrinogen as a major cardiovascular risk factor in cardiovascular disease. Trends Pharmacol Sci 1990; 11: 444-51.
142. Thompson WD, Smith EB. Atherosclerosis and the coagulation system. J Pathol 1989; 159: 97-106.
143. Smith EB, Keen GA, Grant A, Stirk CH. Fate of fibrinogen in human arterial intima. Arteriosclerosis 1990; 10: 263-75.
144. McDonagh J Suppression of plasminogen binding to fibrin by high fibrinogen: a mechanism for how high fibrinogen enhances the risk of thrombosis Bulletin CML-Thrombosis 1993; 3: 2-20.
145. Hicks RCJ, Golledge J, Mir-Hasseine R, Powell JT. Vasoactive effects of fibrinogen on saphenous vein. Nature 1996; 379: 818-20.
146. Ernst E. Fibrinogen as a cardiovascular risk factor - relationship with infections and inflammation. Eur Heart J 1993, 14 (suppl K) 82-87
147. Spodick DH. Inflammation and the onset of myocardial infaction. Ann Int Med 1985; 102: 699-702.
148. Maseri A, Biasucci LM, Liuzzo G. Inflammation in ischaemic heart disease. BMJ 1996; 312: 1049-50
149. Haverkate F. Low-grade acute-phase reactions in arteriosclerosis and the consequences for haemostatic risk factors. Fibrinolysis 1992; 6 (suppl 3). 17-18.
150. Jang IK, Lassila R, Fuster V. Atherogenesis and inflammation. Eur Heart J 1993; 14 (suppl K): 2-6.
151. de Maat MPM, Pietersma A, Kofflard M, Sluiter W, Kluft C. Association of plasma fibrinogen levels with coronary artery disease, smoking and inflammatory markers. Atherosclerosis 1996, 121: 185-91.
152. Alexander RW. Inflammation and coronary artery disease. N Engl J Med 1994; 331. 468-69.
153. van der Wal AC, Becker AE, van der Loos CH, Das PK Site of intimal rupture or erosion of thrombosed coronary atherosclerotic plaques is characterized by an inflammatory process irrespective of the dominant plaque morphology. Circulation 1994; 89: 36-44.
154. Ernst E, Hammerschmidt DE, Bagge U, Matrai A, Dormandy J. Leukocytes and the risk of ischemic diseases J Am Med Assoc 1987; 257: 2318-24.
155. Liuzzo G, Biasucci LM, Gallimore JR et al. Prognostic value of C-reactive protein and plasma amyloid A protein in severe unstable angina. N Engl J Med 1994; 331: 417-24.
156. Kannel WB, Anderson K, Wilson PWF. White blood cell count and cardiovascular disease. Insights from the Framingham Study J Am Med Assoc 1992; 267: 1253-56.
157. Ernst E, Resch KL. Therapeutic interventions to lower plasma fibrinogen concentration. Eur Heart J 1995; 16 (suppl A). 47-53.
158. Farnier M, Bonnefous F, Debbas N, Irvine A. Comparative efficacy and safety of micronized fenofibrate and simvastatin in patients with primary type IIa or IIb hyperclipidemia. Arch Int Med 1994; 154: 441-49.
159. Kehely A, Mac Mahon M, Barbir M et al. Combined bezafibrate and simvastatin treatment for mixed hyperlipidaemia QJM 1995; 88: 421-27.
160. Ericsson CG, Hamsten A, Nilsson J, Grip L, Svane B, de Faire U. Angiographic assessment of effects of bezafibrate on progression of coronary artery disease in young male postinfarction patients. Lancet 1996; 347: 849-53.
161. Nabulsi AA, Folsom AR, White A et al. Association of hormone-replacement therapy with various cardiovascular risk factors in post-menopausal women. N Engl J Med 1993, 328: 1069-75.
162. Goerdt C, Bloomfield Rubins H, Swaim W, Folsom A. Can phenytoin lower plasma fibrinogen concentrations. Thromb Res 1995; 79: 231-36.
163. The EPIC Investigators Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIa receptor in high risk coronary angioplasty. N Engl J Med 1994; 330: 956-61
164. Seidel D, Armstrong VW, Schuff-Werner P. The HELP LDL-apheresis multicenter study. Clin Invest 1991; 21: 375-83.
165. Koenig W. Establishing causality: the case of fibrinogen. In: Ernst E Koenig W, Lowe GDO, Meade TW eds. Fibrinogen, a 'new' cardiovascular risk factor. Oxford: Blackwell, 1992: 96-100.